Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc. (NASDAQ: COCO) files reports and disclosures with the U.S. Securities and Exchange Commission as part of its obligations as a public company. This page compiles those SEC filings and pairs them with AI-powered tools that help explain the information contained in key documents.
Through its filings, the company reports on topics such as quarterly and annual financial performance, business developments, and regulatory matters. Recent Form 8-K filings, for example, reference press releases announcing financial results for quarters ended June 30 and September 30, 2025, as well as a company statement regarding tariff relief affecting coconut water products. These filings provide detail on net sales, gross profit, net income, and non-GAAP measures like Adjusted EBITDA, along with management’s commentary on factors such as tariffs, costs, and demand for Vita Coco Coconut Water and related products.
On this page, users can access core documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K as they become available through EDGAR. AI-generated summaries are designed to highlight major themes, clarify technical language, and surface items that may matter to shareholders, such as segment performance, tariff discussions, or capital allocation programs mentioned in earnings releases.
In addition, this page provides convenient access to insider transaction reports on Form 4 and other ownership-related filings when they are filed. Together, these resources allow investors, analysts, and interested readers to review The Vita Coco Company’s regulatory disclosures in one place, with AI assistance to make complex filings easier to understand.
Vita Coco Company, Inc. (COCO) director Ira Liran reported the sale of 40,000 shares of common stock on 10/29/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $45.577, with individual transactions ranging from $44.07 to $48.00.
Following the transactions, Liran held 558,341 shares directly and 692,579 shares indirectly through the Ira Liran 2012 Family Trust.
Vita Coco (COCO) Executive Chairman and Director Michael Kirban reported open‑market sales made under a Rule 10b5‑1 trading plan. He sold 30,000 shares at $45.701 on 10/29/2025 and 14,898 shares at a weighted average price of $44.211 on 10/30/2025.
The 10/30 transactions occurred in multiple trades between $44.00 and $45.00. Following the reported sales, beneficial ownership reported included 1,484,151 shares held indirectly by the Michael Kirban 2010 Trust, plus 127,629 shares held directly and 615,681 shares held indirectly by the Michael Kirban Revocable Trust.
Reported derivative holdings include non‑qualified stock options to purchase 546,000 shares at $10.178 expiring 12/16/2029 (fully vested), 298,507 shares at $15 expiring 10/21/2031, and 70,715 shares at $32.78 expiring 03/03/2035, among others, with specified vesting schedules.
Vita Coco (COCO) reported insider activity by Chief Operating Officer Jonathan Burth. On 10/29/2025, he exercised stock options at $10.178 per share for 2,334 and 20,000 shares (code M), then sold the same amounts (code S) at weighted average prices of $47.948 and $45.711, respectively, pursuant to a Rule 10b5-1 trading plan.
Following these transactions, Burth directly beneficially owned 76,127 shares of common stock. The filing also lists multiple outstanding non-qualified stock options with stated exercise prices and expirations, including grants expiring between 2029 and 2035, with various vesting schedules as disclosed.
Vita Coco (COCO) CEO and Director Martin Roper filed a Form 4 reporting open-market sales of common stock on 10/29/2025 and 10/30/2025 made under a Rule 10b5-1 trading plan.
Direct transactions included 5,000 shares at a weighted average price of $46.087 on 10/29 and 500 shares at $45.00 on 10/30. Indirect transactions included 5,000 shares at a weighted average $46.108 on 10/29 and 500 shares at $45.00 on 10/30 by the Christopher G. Roper Exempt Family Trust, plus 5,000 shares each on 10/29 by the Peter S. Roper and Thomas L. Roper Exempt Family Trusts at weighted average prices within the disclosed ranges.
Following these transactions, reported beneficial holdings were 281,562 shares (direct), 215,631 (Christopher G. Roper Exempt Family Trust), 216,131 (Peter S. Roper Exempt Family Trust), 216,131 (Thomas L. Roper Exempt Family Trust), and 61,200 (by spouse).
The Vita Coco Company (COCO) reported higher Q3 2025 results. Net sales were $182.3 million versus $132.9 million a year ago, with gross profit of $68.7 million versus $51.6 million. Income from operations rose to $27.9 million from $20.6 million, and net income was $24.0 million versus $19.3 million. Diluted EPS was $0.40 compared with $0.32. For the nine months, net sales reached $482.0 million and net income was $65.8 million, with diluted EPS of $1.10.
Cash and cash equivalents were $203.7 million as of September 30, 2025. The company had no borrowings and $60.0 million available under its amended revolving credit facility, now maturing in 2030. Two customers accounted for 45% of year-to-date net sales. The board expanded the share repurchase authorization to $65.0 million; year-to-date repurchases totaled 338,416 shares for $10.2 million, leaving $42.0 million authorized. Management highlighted U.S. tariffs, citing a current blended rate of about 23% based on quarter-end sourcing, with review scheduled in November 2025.
The Vita Coco Company, Inc. (COCO) furnished an update on its operations by announcing financial results for the three months ended September 30, 2025. The results were disclosed through a press release furnished as Exhibit 99.1 to a Form 8-K under Item 2.02. The company noted that the information is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.
Vita Coco Company (COCO) reported an insider transaction by a director. On 10/15/2025, the reporting person sold 3,900 shares of common stock at a weighted average price of $38.915 under a Rule 10b5-1 trading plan. Following the sale, the insider directly beneficially owns 619,966 shares.
The filing also lists a non-qualified stock option to buy 27,300 shares at an exercise price of $10.178, fully vested and currently exercisable, with an expiration date of 01/02/2030.
Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported sales of a total of 7,894 shares of common stock on 10/07/2025 under a Rule 10b5-1 trading plan at weighted average prices in the range of approximately $42.51–$42.91. After the transactions the filing reports 287,062 shares beneficially owned directly and 221,131 shares held indirectly through family trusts. The filing also discloses outstanding non-qualified stock options exercisable for 1,099,460 shares in aggregate, with several option grants fully vested and others vesting in scheduled installments through 2035. The sales were effected pursuant to a pre-established plan and the form was signed by an attorney-in-fact on behalf of the reporting person.
Vita Coco Company, Inc. (COCO) reported insider sales by Martin Roper executed under a Rule 10b5-1 trading plan. The filing shows multiple dispositions of 5,000 shares on 10/03/2025 and 10/06/2025, with reported weighted-average prices around $42.6–$42.9. After the reported sales, Mr. Roper directly beneficially owned 293,897 shares and held indirect interests through family trusts and related parties; several family trusts show remaining indirect holdings in the low- to mid-200,000s.
The form also lists fully vested and exercisable non-qualified stock options and other option grants: a large exercisable option for 579,670 shares at an exercise price of $10.178, plus additional option tranches totaling several hundred thousand shares with exercise prices from $10.178 to $32.78 and various vesting/expiration dates through 2035. The sales were made pursuant to a 10b5-1 plan; the filer offered to provide transaction-level price details on request.
Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported multiple sales of company common stock under a Rule 10b5-1 trading plan executed on 10/01/2025 and 10/02/2025. The filings show repeated disposals of 5,000-share blocks at weighted average prices in the low $42 range (reported ranges between $41.79 and $42.66). Following the reported 10/01 sale the filing shows 303,897 shares beneficially owned directly; following the 10/02 sale that direct ownership is shown as 298,897. The Form 4 also discloses multiple indirect holdings by related family trusts and a spouse, and reports several non-qualified stock options with exercise prices from $10.178 to $32.78, some fully vested and currently exercisable and others subject to multi-year vesting schedules.